Question to the Department of Health and Social Care:
To ask Her Majesty's Government how much income they have received from the profit cap in the Pharmaceutical Price Regulation Scheme since 2014; and to which department the rebate is paid.
Under the 2014 Pharmaceutical Price Regulation Scheme (PPRS), scheme members make payments to the Department based on the difference between allowed percentage growth rate and actual percentage growth rate in National Health Service expenditure on branded medicines.
The 2014 PPRS has now delivered over £2.1 billion of PPRS payments.
Year | Aggregate PPRS Payments |
2014 | £311 million |
2015 | £846 million |
2016 | £628 million |
2017 Q1 | £95 million |
2017 Q2 | £95 million |
2017 Q3 | £97 million |
2017 Q4 | £99 million |
The Department receives the income on behalf of the United Kingdom, and then apportions the monies between the four countries. All funds are reinvested in health services for patient benefit.
Following normal Government accounting rules, there is no separately identified or ring-fenced funding stream associated with PPRS payments.